This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Morgan Stanley Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
In a report released today, Laurence Tam from Morgan Stanley maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$50.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Tam is ranked #9936 out of 12188 analysts.
Currently, the analyst consensus on Wuxi Biologics (Cayman) is a Strong Buy with an average price target of HK$45.33.
Based on Wuxi Biologics (Cayman)’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$11.64 billion and a net profit of HK$2.53 billion. In comparison, last year the company earned a revenue of HK$10.1 billion and had a net profit of HK$1.86 billion
Read More on WXIBF:
Disclaimer & DisclosureReport an Issue
- WuXi Biologics: Robust Backlog, High-Margin Growth Drivers, and Capacity Expansion Underpin Buy Rating
- Wuxi Biologics Grants 25.6 Million Restricted Shares Under Incentive Scheme
- WuXi Biologics Schedules Briefings on 2025 Annual Results for Global Investors
- Wuxi Biologics Delivers Strong 2025 Profit Growth as Project Portfolio Expands
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
